Key Considerations for Development and Production of Vaccine Products - Challenges of vaccine development include regulatory, technical, and manufacturing hurdles in translating a vaccine candidate in

ADVERTISEMENT

Key Considerations for Development and Production of Vaccine Products
Challenges of vaccine development include regulatory, technical, and manufacturing hurdles in translating a vaccine candidate into a commercial product.


BioPharm International Supplements
Volume 25, Issue 3, pp. s28-s34

REFERENCES

1. Fetzer S, BioPharm. Int. 21 (1), s1–s6 (2008).

2. Vaccine http://Ethics.org/, "The Vaccine Industry— An Overview," http://www.vaccineethics.org/issue_briefs/industry.php, accessed Feb. 2012.

3. Kalorama Information, http://www.kaloramainformation.com/, accessed June 22, 2009.

4. PhRMA, "Report on Biotechnology Medicines in Development", 2008, http://www.pharma.org/, accessed June 22, 2009.

5. G. Dietrich et al., "Manufacturing of Vaccines," In New Generation Vaccines, M.M. Levine et al., Eds., (Marcel Dekker, New York, 2004) pp. 1081–1091.

6. P. Gagnon GEN 28 (14), (2008).

7. J.B. Ulmer, U. Valley, and R. Rappuoli, Nat. Biotechnol. 24, 1377–1383 (2006).

8. B. Metz et al., Vaccine 20, 2411 (2002).

9. S. Becht, X. Gu, and X. Ding, Biopharm Int. 20 (8), 1–7 (2007).

10. H. S. Seo et al., Vaccine 26, 4138 (2008).

11. N.W. Baylor, supplement to BioPharm Int. 20(8), 6–15 (2007).

12. S. Scott, BioProcess Int. 8 (s8), 36–42 (2010).

13. D.I. Freedberg, "Improvement of Biological Product Quality by Application of New Technologies to Characterize of Vaccines and Blood Products: NMR Spectroscopy and Light Scattering," http://www.fda.gov/biologicsbloodvaccines/scienceresearch/biologicsresearchareas/ucm127270.htm.

14. G. Healy, "Vaccine production and development: The challenges of realizing a future free from disease," Microbiologist March 28–30 (2006).

15. A.S. Rathore and H. Winkle, Nat. Biotechnol. 27, 26–34 (2009).

16. A.S. Rathore AS, Trends Biotechnol. 27, 546–553 (2009).

17. "Q&A: Good Manufacturing Practice (GMP)," http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000027.jsp&jsenabled=true.

18. FDA, General Principles for the Development of Vaccines to Protect Against Global Infectious Diseases (Rockville, MD, Dec. 2011).

19. Meningitis Vaccine Project, "Regulatory and prequalification pathways," http://www.meningvax.org/regulatory-prequalification.php. accessed Feb. 2012.

20. K.J. Rambhia et al., Biodefense Strategy, Practice, and Science 8 (4), 321–330 (2010).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here